TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19111278
Drug: d‐amphetamine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine (20 mg)
Study: 18831930
Drug: Inhaled thiamphenicol
Normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled thiamphenicol associated with acetylcysteine (250 mg: 1/2 vial in the morning and 1/2 vial in the evening) for 5 days (Group A)
Study: 18831930
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution twice daily for 5 days (Group B)
Study: 15838660
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: Docetaxel 60 mg/m² over 1 hour followed by Topotecan 0.85 mg/m² continuous infusion over 72 hours
Study: 15838660
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: Topotecan 0.85 mg/m² continuous infusion over 72 hours followed by Docetaxel 60 mg/m² over 1 hour
Study: 10517908
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg oral diltiazem
Study: 10517908
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily diltiazem
Study: 10517908
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily diltiazem
Study: 10517908
Drug: 0.1% bethanechol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bethanechol gel
Study: 7563935
Drug: Non-G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-G-CSF
Study: 1891681
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide aerosol (400 micrograms once daily)
Study: 1891681
Drug: Budesonide dry
Normalized name: budesonide Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide dry powder (400 micrograms once daily)
Study: 6337323
Drug: Refractoriness to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractoriness to random-donor platelet infusions at transplantation
Study: 30745097
Drug: NIT+IPC (NO3‐‐rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIT+IPC (NO3‐‐rich gel ingested 90min prior to testing)
Study: 30452209
Drug: Extended-release injectable
Normalized name: Exenatide for Extended-Release Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release injectable naltrexone (XR-NTX)
Study: 23082885
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) therapy
Study: 15997317
Drug: Yellow fever
Normalized name: yellow fever live
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yellow fever vaccines (WHO‐17D and Brazilian 17DD substrains)
Study: 6987026
Drug: Aspirin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,000 mg)
Study: 10051263
Drug: Paracetamol (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1,000 mg)
Study: 7006441
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with bupivacaine 0.5% (mean dose 112.8 mg)
Study: 7006441
Drug: Pethidine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (mean dose 200 mg) and inhalational analgesia
Study: 23380214
Drug: Collateral Meridian
Normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collateral Meridian (CM) therapy
Study: 20353746
Drug: Modified-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release formulation of diltiazem hydrochloride (240 mg dose)
Study: 20353746
Drug: Formulation 3
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation 3
Study: 20353746
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with highest amount of polysaccharide in coating
Study: 15890735
Drug: Delayed hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed hCG administration (late-hCG group, n = 5)
Study: 15890735
Drug: Early hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early hCG administration (early-hCG group, n = 5)
Study: 12235246
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oral folic acid for 6 weeks
Study: 2206072
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (2.5 mg)
Study: 23263970
Drug: Lingual 24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingual 24% sucrose (1 ml) administered 2 min before OGT insertion
Study: 23263970
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (1 ml) administered 2 min before OGT insertion (Placebo)
Study: 15925045
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 50 microg misoprostol (n=100)
Study: 9862846
Drug: trapidil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: trapidil (400 mg/d) and ticlopidine (250 mg/d)
Study: 9862846
Drug: heparin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin treatment (12 to 24 U/kg bolus, 1 week intravenous, 4 weeks subcutaneous)
Study: 29261824
Drug: Varenicline tartrate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline tartrate, 1mg twice daily for 16 weeks
Study: 19230767
Drug: Low GI
Normalized name: Yellow Ginger Root
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low GI meal (1 g kg(‐1) body mass of carbohydrate, consumed 45 min prior to TT)
Study: 7719946
Drug: Various pharmacologic
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacologic agents used in the treatment of CHF, specific dosages and durations not mentioned.
Study: 7719946
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies for CHF, specific agents not mentioned.
Study: 1007937
Drug: Unilateral, non-dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral, non-dominant ECT with four treatments weekly
Study: 1007937
Drug: Unilateral, non-dominant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral, non-dominant ECT with two treatments weekly
Study: 30004111
Drug: DEFA5 rs4415345
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEFA5 rs4415345 G vs. C
Study: 21155012
Drug: CPT‐11‐containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11‐containing combination chemotherapy
Study: 15099661
Drug: Risk reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk reduction intervention focusing on safer injection and sex behaviors
Study: 15099661
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing addressing lifestyle changes including drug treatment
Study: 15099661
Drug: Free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free treatment (coupon for 90 days)
Study: 12369794
Drug: Hormone-replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-replacement therapy (HRT; 1 mg of 17beta-estradiol combined with 0.5 mg of norethisterone acetate)
Study: 2718973
Drug: Vasoconstricting nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstricting nasal spray
Study: 31773885
Drug: Geriatric Emergency
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric Emergency Department Intervention (GEDI) model; nurse-led, physician-championed intervention; details on dosage and duration not specified.
Study: 25212229
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - high dose
Study: 25212229
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - medium dose
Study: 25212229
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) - low dose
Study: 22864620
Drug: 0.4% glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% glyceryl trinitrate (GTN) ointment
Study: 22864620
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no GTN ointment)
Study: 19451915
Drug: Risperidone 2-6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 2-6 mg per day over 2-12 weeks
Study: 15605131
Drug: Nurse-administered massage
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered massage and breathing techniques during latent phase of labour
Study: 11164149
Drug: PSA cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA cutoff of 3.0 ng/mL or greater
Study: 11164149
Drug: PSA cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA cutoff of 4.0 ng/mL or greater
Study: 11164149
Drug: PSA range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA range 3.0 to 3.9 ng/mL (new protocol)
Study: 11164149
Drug: PSA range
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA range 3.0 to 3.9 ng/mL (original protocol)
Study: 11164149
Drug: PSA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA levels less than 2.9 ng/mL
Study: 9227295
Drug: Oral aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aminophylline
Study: 3115843
Drug: Metformin (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1.75 g for 15 days)
Study: 24746000
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg three times a week for 12 months
Study: 11137723
Drug: Cold applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold applied for 5 min before injection
Study: 11137723
Drug: Cold applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold applied for 5 min after injection
Study: 11137723
Drug: Cold applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold applied for 5 min pre and post injection
Study: 7513876
Drug: Pharmacotherapy guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy guided by suppression of spontaneous arrhythmias
Study: 7513876
Drug: Pharmacotherapy guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy guided by suppression of stimulation‐inducible VT/VF
Study: 7513876
Drug: Sodium channel
Normalized name: Sodium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium channel blockers (imipramine, mexiletine, procainamide, propafenone, pirmenol, quinidine)
Study: 30415553
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d folic acid supplements
Study: 27562972
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (rapid intravenous infusion of up to 2 L of cold saline)
Study: 9844955
Drug: Drug-free condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free condition
Study: 11498318
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ephedrine
Study: 11498318
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ephedrine
Study: 11498318
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ephedrine
Study: 8989009
Drug: Crystalloid prehydration
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid prehydration (500 mL Hartmanns solution, n = 29)
Study: 8989009
Drug: Colloid prehydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid prehydration (500 mL Haemaccel, n = 28)
Study: 31705339
Drug: Probiotics (Gynophilus®)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Gynophilus®) with metronidazole (500 mg twice a day)
Study: 31705339
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with metronidazole (500 mg twice a day)
Study: 29049211
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg 24 hours preoperative administration (EPEA)
Study: 29049211
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg 1 hour preoperative administration (PEA)
Study: 29049211
Drug: Celecoxib 400mg
Normalized name: CELECOXIB 400MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400mg 4 hours postoperative administration (POA)
Study: 25311651
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (20 mg L, 2 mg Z, 0.3 mg MZ)
Study: 25311651
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (10 mg L, 2 mg Z, 10 mg MZ)
Study: 25311651
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (3 mg L, 2 mg Z, 17 mg MZ)
Study: 18650802
Drug: Rotigotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (4 mg/24 h to 24 mg/24 h)
Study: 10941718
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (100 micrograms of selenomethionine daily)
Study: 8473421
Drug: Modified swim-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified swim-up sperm preparation
Study: 8473421
Drug: Percoll sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percoll sperm preparation
Study: 8473421
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no sperm preparation
Study: 27055853
Drug: Sequential learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential learning (SEQ)
Study: 20818888
Drug: Icatibant (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icatibant (30 mg subcutaneously)
Study: 15875527
Drug: Cetirizine hydrochloride,
Normalized name: Cetirizine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine hydrochloride, 10 mg/d
Study: 15875527
Drug: Fexofenadine hydrochloride,
Normalized name: Fexofenadine Hydrochloride, 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine hydrochloride, 120 mg/d
Study: 15875527
Drug: Loratadine, 10
Normalized name: Loratadine, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine, 10 mg/d
Study: 15875527
Drug: Placebo (lactose),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose), twice daily
Study: 10451399
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 0.9 mg/litre iron
Study: 10451399
Drug: Formula containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula containing 1.2 mg/litre iron
Study: 30518646
Drug: gB/MF59 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: gB/MF59 vaccine
Study: 26607778
Drug: Adjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant concurrent chemoradiotherapy followed by chemotherapy
Study: 20027352
Drug: Anaferon in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaferon in complex therapy
Study: 15494201
Drug: Sedative music
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative music (30 min)
Study: 9749809
Drug: Educational game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational game (G)
Study: 7849442
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms bolus followed by continuous intravenous infusion at 25 micrograms/h for 24 hours; 100 micrograms t.i.d. subcutaneously for 6 days)
Study: 7849442
Drug: Terlypressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlypressin (2 mg intravenous bolus every 4 hours for 24 hours; 2 mg every 6 hours on the 2nd day; 1 mg every 6 hours from the 3rd to 7th days)
Study: 3059450
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (3 g)
Study: 3059450
Drug: prednisolone phosphate
Normalized name: Prednisolone phosphate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone phosphate sodium (30 mg)
Study: 30726338
Drug: Teaching program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teaching program for hospital discharge (oral guidance, written instruction, telephone follow-up)
Study: 28806992
Drug: Self-directed program
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed program (provision of printed intervention materials but no additional treatment visits)
Study: 25415805
Drug: Patiromer (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (4.2 g or 8.4 g twice a day for 4 weeks)
Study: 22433185
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg L-759274
Study: 22433185
Drug: 1-6 mg
Normalized name: riboflavin 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-6 mg lorazepam
Study: 16882822
Drug: Brief psychosocial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychosocial support from a member of the primary care team, with or without medication
Study: 16882822
Drug: Indirect psychosocial/behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect psychosocial/behavioral interventions (e.g., anticipatory guidance, treatment adherence)
Study: 12821755
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (anticholesterol drugs)
Study: 10849926
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution in Myvacet 9-08
Study: 10849926
Drug: Suspension of
Normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of phenobarbital
Study: 10849926
Drug: Tablet of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet of phenobarbital
Study: 8992495
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) administration
Study: 1379106
Drug: alfuzosin 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 1.25 mg
Study: 1379106
Drug: alfuzosin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 2.5 mg
Study: 6707391
Drug: PRW therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRW therapy (4 injections)
Study: 6707391
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (4 injections)
Study: 26729211
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (L)
Study: 26729211
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose (M)
Study: 26729211
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (H)
Study: 20674390
Drug: Progressive exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive exercise program with weekly supervision
Study: 18166815
Drug: Repaglinide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (2 mg thrice daily)
Study: 10616075
Drug: N-methyl-D-aspartate antagonist
Normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-methyl-D-aspartate antagonist Selfotel
Study: 9169302
Drug: Inositol 12
Normalized name: inositol 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 12 g daily for 4 weeks
Study: 9169302
Drug: Inositol 18
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol 18 g for 6 weeks
Study: 9169302
Drug: Inositol 12
Normalized name: inositol 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 12 g daily for 1 month
Study: 9169302
Drug: Inositol 6
Normalized name: inositol 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 6 g daily for 1 month
Study: 9169302
Drug: Inositol 200
Normalized name: inositol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 200 mg/kg body weight for 8 weeks
Study: 9169302
Drug: Inositol 200
Normalized name: inositol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 200 mg/kg daily for a crossover trial
Study: 9169302
Drug: Inositol 6
Normalized name: inositol 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 6 g daily for 5 days before ECT
Study: 8289407
Drug: GLN-containing total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLN-containing total parenteral nutrition (TPN) (40 g of glutamine total)
Study: 8289407
Drug: Standard total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard total parenteral nutrition (TPN) (control)
Study: 3026015
Drug: Sulbactam (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactam (50 mg/kg per day) and ampicillin (400 mg/kg per day)
Study: 28630358
Drug: rVSVΔG‐ZEBOV‐GP vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSVΔG‐ZEBOV‐GP vaccine
Study: 30275753
Drug: Radial shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shockwave therapy (0.17mJ/mm2, 100 impulses/cm2, 5 Hz)
Study: 30275753
Drug: Focused shockwave
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shockwave therapy (0.173mJ/mm2, 100 impulses/cm2, 5 Hz)